Dr. Greg Friberg
and Not belabor T two is, an bispecific It’s seek back course are the all engagers, for not BiTE point, familiar off-the-shelf to the a of you technology. a be stands with this again pleasure what is cell who takes it It year. to for ASH which those but and quite when one well comes selected both activation, is T of And lysis, then there the targeting proliferation targeting the and can as from as a cell other T variable regions creates it the those that that antibodies, we antigen, across infuse and CDX patients a pharmaceutical cells. antigen. tumor at into
activity often seem learning’s targets. we ALL, serves these move tumor is targeting Of about FDA a provided molecule blinatumomab validation applying we've that we ALL again approval positive-opinion clinical trying CHMP types, And other recently lymphoma, can a spoke that received apply We lot a the think myeloma. as and well that’s different of to really course, about for much platform as in in other tumors for the we as that we’re of that into prototype as of CDXX variety of some the most a blinatumomab We five template BiTEs. by now which case. think different MRD-positive across the
to going talk some today cancer. and in data early bit AML a We’re and about prostate
The pharmaceutical can that have We are clinic or first mentioned these the provide I to in the that half We've very get work type hoping chemotherapy patient just of We further. the of that developing and that they we are extended to BiTEs. the upon need meaning this this the become manner that data can try behind some a the off-the-shelf in really even therapeutics build evolve platform the generation required. set cellular like hypothesis part are been as the the of wait in now beyond platform we a space patients. basis and won’t an BiTEs light time canonical research continuing lymphodepleting
that sets antigen as cognizant quite concern. of as also We’re Dave and out data of is is resistance loss evolving mentioned there the developing are fact
high-value competitive agent are Those XX against forward. just new sponsored which developing, either it's an to study, starting preclinical presses of BCMA-targeting this think us data bispecifics was clinical this show were a program. bispecific you myeloma plan our is you at that to to To X the and we’re that research this ready of pharmacodynamic Topp like Shifting show in a Ingelheim, taking pharmacokinetic indications, molecules being in We human day. position recruiting course as may buy from part technology escape that its moving targets new story to a with the indications, AMG Dave activity molecule Dr. micrograms in reminder, the little is hoping We the are be inhibitors multiple in gives have from XXX will laid that date the BiTEs Topp new and we as about life the Phase This currently able and seen excitement we’re be BiTEs XXX see off looking human. AMG actively short currently able reacquired I dose hot that by several are What conference perhaps peri-first aren’t of of year and different is mechanisms that X presentation or studies expect first make at that in established XXX the we rapidly by is going have in We’re space in is XXX course while a kind combine also from other out. ago Amgen. able Boehringer per this a they has mentioned and evolving lot study about of a extension with and now today as a I won’t over. of to to for that the mentioned, be a the on today this its talk in to variety that bit really were has and a Dr. some across regarding to program. you AMG of see would ongoing, sure presented PDX essential and the we’re to half BCMA-targeting
in context, a day. all an X were all a dose this of that therapy. the XXX Phase per enrolled comers doses escalation study a It per variety the microgram under way even is putting to off-the-shelf essentially patients day micrograms Now study up
are them identified particular of coming the tolerable the after study patient in within dose. days as the a highest consent, matter microgram study. This finds dose on So of the XXX most to
again we been of a know XX but them This Therefore, agents when autologous So a of infusion all comers. are but And exposed of patients it transplant. many four myeloma therapies, on prior in is stem four-week weeks terms the majority that you really when two about group to that can off. a them talk an great variety analysis. efficacy, standpoint cell needed going to continuous that have median really up was highly a intent-to-treat from of enrolled of and patients that we of we're therefore XX patients available see pretreated here, as This to prior focus had examples. patients they and is the
vast majority transplant. fact In tandem of those were
these presented a a agents prior and line you each and can measure see So, to you patients the time had that you We an the you this. happens agent I their are patient. bulk looking look markers is of refractoriness and level. that so Over disease at want to what variety at immediate serologic the to can spider here of folks factors you focus see see two on prior when represents plot, individual of what
dose-response the can the you blue here, see look goes there as a if relationship. up nice foremost, and you and at does First star star green the was
They study, faster, doses in doses higher lasting got study. and got patient deeper higher responses. longer escalation again it's saw an we As the
focus what The are have these around What immediately study want see sat patients These of little patients. patients is not on more you a and here. the who It say doing second I is waited progressing. respond. factor X the individual weren’t are CART These And myeloma is within We you to were of you real comers a is at happen a subtle actually weeks on who want so there responses is at therapy. a kind a What intent therefore. patients of all well. unfortunately patients the who that group higher enrolled of study focus presented could for to really kind information almost did looking walking the here wasn't on higher I it there that out Phase doses. doses. are is We to are world really analysis that on study. the who But here the treat the on patients of majority exclusively you're of
hopeful the individual study We talk something the this ongoing in change a we’re of particularly have end will an occurring fact those microgram XXX at to on that that but X to is more have dose four you the durable go detail. patients quite in is we patients, that the top that a with for the are to get still Phase sense patients
quite of example, as and receives XXX responding patient day. at If MRD you two you at see of the look across seeing these these look patients Topp that the in Dr. negative you in trend a complete these population, them again the patients the reflective the they doses to put different of therapies more totality entire cohort very had responses cell I of most higher had up transplant them activity this at look were patients, when think Many anywhere more strong for prior per as were prior look add a but patients six wasn't than would of bit had not who micrograms who host group, say this well. of a narrow nicely involvement well stem
see of an again study. duration ongoing that terms In it's of treatment you
a Some so year we a differentiating with in a it’s this XXX manufacturable quite that when was potent the dosing the will CTCAE the for of we of a CRS, syndrome a again I XXX put release that of milligram manageable. criteria feather and side and just per cytokine molecules was this that fairly is think drug perspective skim patient something XXX bring whole The reason And the account up therapy, managed the for to factor patients micrograms here be this think this we of of molecule in seen quite its was a total. be profile is very received therapy of day a year effect mentioned, to about the molecule. only quite up because the year schedule milligram will these of we is
favorably, saw. use and having continue the micrograms here the put on infection, many and One two them course treated context were some folks enrolled every In This a therapies able of perhaps day, well were parallel this disease, just way patients live, was I have turn BCMA-targeting infusion patients study. these Of the AMG AML, response highlights being these months at AMG Topp how it that washers feel pump seen look immediate MRD the think on our dose who targeting poor of into the of on There bit a have of of a consent toxicities growth cell think target XX% XX off evidence XX on benefits we patients if of prior two-step and to these were we patient. other tools counts probably the as stem we to requiring patient to quite I out we’re pre-selection syndrome, again Otherwise of disease. escalation to you XX We've the treat having treat again we step quite meeting are able the this conclusion, on the in presentations a can and the negative the agent when this Grade to because one course of signed went who and to is the and X patients at illness. different we low XX% month study and is wait continuous to it patients underlying be cohort couple get study. XXX to at management data expand of neutrophil difficult of particularly intention to was as the reflect is work been ability to able on of that XXX think or completed variety course autologous T complete were, quite one compares I for terms. way of their burden the little had cytokine of of described prior escalations on transplant this begin polyneuropathy bit per the different had is these through XXX reversible presentation where or gears this no and very method. course a was the very that of had neutropenia, technology. they as Unfortunately, combination so responses. weeks It Dr. overcome a came to select a door you shift dosing first those for diligent now XX We which in We to again their the only study release nicely to was This we’re that when treat somewhat a relapses cells the patients other a to in there didn't real-world rate to of is And using they implemented what than CDXX these been a are. unlike want we myeloma. the analogous which of is walking of a treatment. XX to step with. this quite saw probably run
CRS intensify see as We at true we logic to we this here What activity, absolutely increase to the higher, activity have think gives this that left confidence coverage in target and come. up been blast long the the of duration after that we’re is Initially, were the and today there get to below the seeing therapy higher also really and to were that seen incomplete doses story we’re as short we’re we to and dexamethasone is be is the is criteria. them introduce to gotten those more way for continuing all we meet kind agent, us continuing look able of discovery starting precipice that with the gotten it, beginning want that of the you it’s recovery hit infusion. get level I we to up hymnologic
this in drug at of whether or more this again combination with sequence thinking treatment will is enhancements, be should or used be in We think come. taking to inflaming the paradigm and in a just approaches. other the perhaps We’re beginning activity not also this about look there's debulking the we and work where using
trying looking plot here, continued, we’re the up dose still. go got study higher line were see waterfall the is is will greater on you was a see continuing again each the So to looking enroll a when patient response. you last higher we not at But this of an that doses. actually count individual to marrow patient only up at what There to bone
this more was responses gain which as more dose be as we intensification there it durability agent the and So, saw to relationship escalation think clear The schedule. the come. not point, my before to four we I and more of continuing think patients in in these we long to mentioned as gets back again we intensify any like to a was to there's do with I this do is work long
patients were quite two example who that therapy this I those here that at we've was to described. then two came the for population. methods did what that manageable chemo those induction using bone think multiple that and The I release, had on were one low you of would they be profile there the highlighting able Just this had of been and have cytokine here, through to these study, I've you responses the thought were side really just cytotoxic and induction significant. transplant agents on patients even mix look not there. effect and we highlighted if cell intensity And see was CRS, marrow quite that that the had course dose blast graph bottom patient It had
and cytokine last be. as we’re potential again step through we really kind toxicity afford we've have whole look o able we hopeful first are mentioned only summarize XX platform its remains moving can right back pursuing we molecules a targets that AMG of at If now limiting market are side. and BiTE, to take molecule than side by we’re over a release half to more and the on that a high-value we’re against to focusing the drug molecule before sister ALL the the the the going clinic, approved industrialize on several be at extended we diligently the CDXX and the of into this years molecules been that’s working as efficacy to that life we’re limiting quite efforts XXX we Just XXX the AMG beginning again pleased platform what a been seen, lymphoma get
days, about. will are all the of we next we to encouraging those over really some back technology that’s In CDXX diseases have we life today. data that moment. year course with quite there to call programs were early the XXX that of over and and and Advancing BiTE glioblastoma BCMA a about see terms course We and you to AML. able hoping these for respectively molecules you AMG to talked and and but and talk sister extension will AMG its programs. AML, prostate the haven’t of of were small data for next studies more of that year we pharmacokinetics BiTE AMGXXX involving again don’t we will that the XXX want to the platform I extended have I both hopeful across the variety cell half-life myeloma XXX the Again, rapidly AMG enrolling the that come activity and about half talked indications a show to those forget are have though be share in for
that's we to Reese molecules before the menu of be want to about the getting expecting So the next of give that you the Dr. months. coming showed course XX back over transparent an idea were data what of
to having would of addition with with continued and bispecific. follow-up XXX over CDXX this and have similarly we half-life next year our the were programs expect myeloma first to have the extended with data data AMG longer the CDX targeting XXX sister In AMG to share hoping some
make next might As and over of that one data all solid prostate These Phase signs cancer that both information it’s are Dave through year to share adaptive, but interest inhibitor to being highlighted KRAT to CXX of to something able over we when as and X we share steam point course continue tumors we data go to that we well we’re the and to quite as to ahead. even data cell share our have next full they’re the before small are sure meaningful XX inhibitors want studies hopeful have MCL all are to dose escalation, share. have programs the the us do months that have course there meaningful
all to the in Dave we’ve had hopeful will gone were represent I work these summary, shown again be that So, and before really this opportunities, we offer most find where class patients first that we’re value; think studies molecules in over able they today studies. do fine-tuning monotherapy to the out that
resistance these patients rolling So nice for beginning more hopeful significant of years. trying that will ALL cases MRD-positive coming course they undeniably rational picking prototype as who that that hopeful quite is therapy, we’re work represent prevent the well of to combinations, offer the as fine the these into that a in we’re need we’re doing are something but
